369: Trump, Chinese biotech, and an industry career reshaped by illness
The Readout Loud
00:00
Biotech in the Crosshairs
This chapter discusses the potential ramifications of a crackdown on Chinese drug licensing by the Trump administration. It highlights the concerns within the U.S. biotech industry regarding regulatory scrutiny and competition with Chinese firms. The dialogue reveals how protectionist policies could hinder innovation and investment in American biotech, while contrasting it with the rapid drug development pace in China.
Transcript
Play full episode
